Boehringer Ingelheim of Germany has entered into an agreement with the UK’s DxS to provide a companion diagnostic test kit for Boehringer Ingelheim’s compound BIBW 2992 (Tovok) to identify EGFR mutations of in patients with non-small-cell lung cancer.
Boehringer Ingelheim of Germany has entered into an agreement with the UK's DxS to provide a companion diagnostic test kit for Boehringer Ingelheim's compound BIBW 2992 (Tovok) to identify EGFR mutations of in patients with non-small-cell lung cancer.
BIBW 2992 is a tyrosine kinase inhibitor that acts by irreversibly blocking the EGFR/HER2 receptors. The DxS EGFR companion diagnostic is a real-time PCR assay designed to detect the most common mutations in the EGFR gene
Eric Ko on Combining Radiation Therapy With Immunotherapy to Treat Non–Small-Cell Lung Cancer
September 18th 2018ONCOLOGY spoke with Eric Ko, MD, PhD, who recently published a review article with his colleagues on strategies for combining radiation therapy with immunotherapy for the treatment of non–small-cell lung cancer.